C4 Therapeutics (CCCC) Price & Analysis

Compare

617 Followers

CCCC Stock Chart & Stats

$2.05

-$0.05(-1.30%)

At close: Jan 08 4:00 PM EST

$2.05

-$0.05(-1.30%)

Day’s Range― - ―

52-Week Range$1.09 - $4.26

Previous CloseN/A

Volume165.25K

Average Volume (3M)1.45M

Market Cap

$219.03M

Enterprise Value$30.67M

Total Cash (Recent Filing)$191.88M

Total Debt (Recent Filing)$61.46M

Price to Earnings (P/E)―

Beta3.45

Next Earnings

Feb 19, 2026

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding96,914,420

10 Day Avg. Volume1,691,882

30 Day Avg. Volume1,447,372

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.16

Price to Sales (P/S)7.02

P/FCF Ratio-3.82

Enterprise Value/Market Cap0.14

Enterprise Value/Revenue1.02

Enterprise Value/Gross Profit1.08

Enterprise Value/Ebitda-0.25

Forecast

1Y Price Target

$7.33

Price Target Upside257.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.42

Revenue Forecast (FY)$31.47M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsCemsi is advancing into a pivotal Phase II (MOMENTUM) trial in 4L+ r/r myeloma, with initial data expected, indicating progress in clinical trials.

Industry PartnershipsC4 has ongoing licensing and collaboration revenue and partnerships with Betta, Biogen, Roche, and Merck KGaA, indicating strong industry connections and potential for further value.

Market PotentialC4 estimates the combined 2L and 4L opportunity to be $2.5-4B of peak revenue, highlighting significant market potential.

Bears Say

Market CompetitionMM remains a highly competitive category, which could pose challenges for market penetration.

C4 Therapeutics News

C4 Therapeutics price target lowered to $5 from $10 at Barclays

Barclays lowered the firm’s price target on C4 Therapeutics (CCCC) to $5 from $10 and keeps an Overweight...

2d ago

CCCC

C4 Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and no price target C4 is...

17d ago

CCCC

C4 Therapeutics files $400M mixed securities shelf

16:09 EST C4 Therapeutics (CCCC) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

27d ago

CCCC

C4 Therapeutics’ Innovative Drug Development and Promising Clinical Trials Support Buy Rating

C4 Therapeutics (CCCC) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler...

17d ago

CCCC

C4 Therapeutics Reports Q3 2025 Financial Results

C4 Therapeutics, Inc. ( ($CCCC) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

CCCC

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

Reports Q3 revenue $11.2M, consensus $6.28M. “Recent months have been transformative for C4T, and we are in a...

1M ago

CCCC

C4 Therapeutics sees cash runway to the end of 2028

Cash, cash equivalents and marketable securities as of September 30, 2025 were $199.8 million, compared to $223.0 million...

1M ago

CCCC

C4 Therapeutics Announces Stock and Warrants Offering

C4 Therapeutics ( ($CCCC) ) has shared an update. On October 16, 2025, C4 Therapeutics announced an underwritten...

2M ago

CCCC

C4 Therapeutics prices $125M underwritten offering

C4 Therapeutics (CCCC) announced the pricing of an underwritten offering to a select group of institutional investors consisting...

2M ago

CCCC

C4 Therapeutics Presents Phase 1 Trial Data

An announcement from C4 Therapeutics ( ($CCCC) ) is now available. On October 16, 2025, C4 Therapeutics announced...

2M ago

CCCC

C4 Therapeutics Partners with Pfizer for Clinical Trial

The latest announcement is out from C4 Therapeutics ( ($CCCC) ). On October 1, 2025, C4 Therapeutics announced...

3M ago

CCCC

C4 Therapeutics announces trial collab, supply agreement with Pfizer

C4 Therapeutic (CCCC) announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer...

3M ago

PFE

CCCC

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on C4 Therapeutics (CCCC) to $10 from $5...

3M ago

CCCC

C4 Therapeutics price target raised to $10 from $8 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on C4 Therapeutics (CCCC) to $10 from $8 and...

3M ago

CCCC

CCCC FAQ

What was C4 Therapeutics’s price range in the past 12 months?

C4 Therapeutics lowest stock price was $1.08 and its highest was $4.26 in the past 12 months.

What is C4 Therapeutics’s market cap?

C4 Therapeutics’s market cap is $219.03M.

When is C4 Therapeutics’s upcoming earnings report date?

C4 Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 62 days.

How were C4 Therapeutics’s earnings last quarter?

C4 Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.406 by -$0.034.

Is C4 Therapeutics overvalued?

According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does C4 Therapeutics pay dividends?

C4 Therapeutics does not currently pay dividends.

What is C4 Therapeutics’s EPS estimate?

C4 Therapeutics’s EPS estimate is -0.29.

How many shares outstanding does C4 Therapeutics have?

C4 Therapeutics has 96,914,420 shares outstanding.

What happened to C4 Therapeutics’s price movement after its last earnings report?

C4 Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.406. Following the earnings report the stock price went up 0.422%.

Which hedge fund is a major shareholder of C4 Therapeutics?

Currently, no hedge funds are holding shares in CCCC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

C4 Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-59.98%

Trailing 12-Months

Asset Growth

-29.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

C4 Therapeutics

C4 Therapeutics (CCCC) is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat cancer and other diseases. The company operates within the biopharmaceutical sector, leveraging its proprietary platform to create a pipeline of drug candidates designed to selectively degrade disease-causing proteins. C4 Therapeutics aims to address unmet medical needs by providing more effective and safer treatment options for patients with various types of cancer.

C4 Therapeutics (CCCC) Earnings & Revenues

Historic Earnings Reports

CCCC Stock 12 Month Forecast

Average Price Target

$7.33

▲(257.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.54,3.113846153846154,3.687692307692308,4.2615384615384615,4.835384615384616,5.40923076923077,5.983076923076924,6.556923076923077,7.130769230769231,7.704615384615385,8.278461538461539,8.852307692307694,9.426153846153847,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.54,2.9084615384615384,3.276923076923077,3.6453846153846152,4.013846153846154,4.382307692307692,4.750769230769231,5.11923076923077,5.487692307692308,5.8561538461538465,6.224615384615385,6.593076923076923,6.961538461538462,{"y":7.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.54,2.729230769230769,2.9184615384615387,3.1076923076923078,3.296923076923077,3.4861538461538464,3.6753846153846155,3.8646153846153846,4.053846153846154,4.243076923076924,4.432307692307692,4.621538461538462,4.810769230769231,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >